26 resultados para Gunston Hall
Resumo:
A linear theory for intermediate-frequency [much smaller (larger) than the electron gyrofrequency (dust plasma and dust gyrofrequencies)], long wavelength (in comparison with the ion gyroradius and the electron skin depth) electromagnetic waves in a multicomponent, homogeneous electron-ion-dust magnetoplasma is presented. For this purpose, the generalized Hall-magnetohydrodynamic (GH-MHD) equations are derived for the case with immobile charged dust macroparticles. The GH-MHD equations in a quasineutral plasma consist of the ion continuity equation, the generalized ion momentum equation, and Faraday's law with the Hall term. The GH-MHD equations are Fourier transformed and combined to obtain a general dispersion relation. The latter is analyzed to understand the influence of immobile charged dust grains on various electromagnetic wave modes in a magnetized dusty plasma. (C) 2005 American Institute of Physics.
Resumo:
A generalized linear theory for electromagnetic waves in a homogeneous dusty magnetoplasma is presented. The waves described are characterized by a frequency which is much smaller (larger) than the electron gyrofrequency (dust plasma and dust gyrofrequencies), and a long wavelength (in comparison with the ion gyroradius and the electron skin depth). The generalized Hall- magnetohydrodynamic (GH-MHD) equations are derived by assuming massive charged dust macroparticles to be immobile, and Fourier transformed to obtain a general dispersion relation. The latter is analyzed to understand the influence of immobile charged dust grains on various electromagnetic wave modes in a magnetized dusty plasma.
Resumo:
Thursday, October 27 · 7:00pm - 8:00pm
Location
Brooklyn College
Studio 312 in Roosevelt Hall, Bedford Ave.
Brooklyn, NY
Created By
Cory Bracken
Resumo:
for piano, violin, violin or viola, cello
Resumo:
G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today. The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these. Thus, there is huge potential in terms of the number of targets for new therapies to be designed. Several breakthroughs in GPCRs biased pharmacology, structural biology, modelling and scoring have resulted in a resurgence of interest in GPCRs as drug targets. Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery. Several key points emerged. Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree. This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept. Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, especially when combined with increasing data regarding allosteric modulation. Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallographic methods. Subtle effects within the packing of the transmembrane helices are likely to mask and contribute to this aspect, which may play a role in species dependent behaviour. This is particularly important because it has ramifications for how we interpret pre-clinical data. In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems associated with the more difficult targets in the future.